Trial reportReproductive biology and endocrinology : RB&E2020
Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: a randomized controlled trial.
Trial report in Reproductive biology and endocrinology : RB&E, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Growth hormone improves the pregnancy outcomes in poor ovarian responders undergoing in vitro fertilization: an umbrella review.Journal of assisted reproduction and genetics · 2025Pooled it
- TEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-ET: a systematic review and network meta-analysis.Reproductive biology and endocrinology : RB&E · 2023Pooled it
- Growth hormone for in vitro fertilisation (IVF).The Cochrane database of systematic reviews · 2021Pooled it
- Effect of acupuncture for poor ovarian response: a multicenter randomized controlled trial.Frontiers in endocrinology · 2026Trial
- Coenzyme Q10 Impact on Ovarian Reserve Measures and the Intra-Cytoplasmic Sperm Injection (ICSI) Outcomes in Women with Poor Ovarian Response: A Randomized Controlled Study.Drug design, development and therapy · 2026Trial
- Astaxanthin treatment decreases pro-inflammatory cytokines and improves reproductive outcomes in patients with polycystic ovary syndrome undergoing assisted reproductive technology: A randomized clinical trial.Inflammopharmacology · 2024Trial
- Growth Hormone Reverses Cisplatin-Induced Ovarian Reserve Depletion in Mice: Transcriptomic Elucidation of Mitochondrial Metabolic Reprogramming and Protein Synthesis Regulation.FASEB bioAdvances · 2026Article
- Impact of inactivated SARS-CoV-2 vaccination on blastocyst euploidy status: a prospective cohort study of patients undergoing preimplantation genetic testing for aneuploidy in China.BMC pregnancy and childbirth · 2026Observational
- Review
- Hyperbaric oxygen therapy improves oocyte yield and embryo quality in poor ovarian responders: a pre-post cohort study.Reproductive biology and endocrinology : RB&E · 2025Article
- Dominant follicle-targeted nanocarriers for GH delivery to alleviate premature ovarian insufficiency.Materials today. Bio · 2025Article
- First follicular fluid cf-mtDNA sequencing unveils ovarian stimulation-induced mutations impacting oocyte quality and IVF success.Journal of assisted reproduction and genetics · 2025Article
- Effects of stress on bone health in children.Frontiers in endocrinology · 2025Review
- The impact of inoculation with the inactivated COVID-19 vaccine on the outcomes ofFrontiers in endocrinology · 2025Article
- An assessment of total antioxidant and oxidant parameters and their correlation with embryo quality in in-vitro fertilization patients.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2025Article
- Novel perspectives on growth hormone regulation of ovarian function: mechanisms, formulations, and therapeutic applications.Frontiers in endocrinology · 2025Review
- The effects of growth hormone supplementation in poor ovarian responders undergoing In vitro fertilization or Intracytoplasmic sperm injection: A systematic review and meta-analysis of randomized controlled trials.Turkish journal of obstetrics and gynecology · 2024Article
- The Double-Edged Sword of Total Antioxidant Capacity: Clinical Significance and Personal Experience.Antioxidants (Basel, Switzerland) · 2024Review
- Enhancing Oocyte Quality in Aging Mice: Insights from Mesenchymal Stem Cell Therapy and FOXO3a Signaling Pathway Activation.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Excess endocrine growth hormone in acromegaly promotes the aggressiveness and metastasis of triple-negative breast cancer.iScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOxidative stress (OS), defined as an imbalance between excessive reactive oxygen species (ROS) and/or reactive nitrogen species (RNS) production and antioxidant insufficiency, has been suggested to be involved in the pathogenesis of poor ovarian response (POR). Growth hormone (GH) can reduce OS in some cell types. This study investigated whether GH can improve OS and the in vitro fertilization and embryo transfer (IVF-ET) outcomes of poor ovarian responders.
methodsThis study enrolled 105 patients with POR and 58 patients without POR (controls) who were diagnosed according to the Bologna criteria and underwent conventional IVF-ET. Poor ovarian responders were randomly assigned to two groups: the POR-GH group, which received pretreatment with GH 4 IU/d on day 2 of the previous menstrual cycle before IVF until the trigger day, and the POR-C group, which received no pretreatment. OS markers in follicular fluid (FF), ROS levels in granulosa cells (GCs), and the IVF outcomes of the groups were compared.
resultsEndometrial thickness on trigger day, the number of cleaved embryos, the number of higher-quality embryos, and the rates of embryo formation, higher-quality embryo formation, implantation and clinical pregnancy were significantly increased in the POR-GH group compared with the POR-C group (P < 0.05). Moreover, compared to those in the non-POR group, FF malondialdehyde (MDA), total oxidant status (TOS), oxidative stress index (OSI) and ROS levels in GCs were significantly higher, whereas superoxide dismutase (SOD) and the total antioxidant capacity (TAC) were significantly lower in the POR-C group (P < 0.05). Furthermore, compared with those in the POR-C group, the FF TAC was significantly increased in the POR-GH group, and TOS, OSI and intracellular ROS levels were significantly reduced (P < 0.05).
conclusionsPretreatment with GH alleviates OS and improves oocyte quality and IVF outcomes of poor ovarian responders.
trial registrationChinese Clinical Trial Registry. ChiCTR1900021269 . Registered 8 February 2019, http://www.chictr.org.cn/edit.aspx?pid=35837&htm=4 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.